Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219901 | 0.92 | FUCA1 (0.48) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL2338541 | 0.92 | MAPT (0.50) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL10513227 | 0.91 | MAOA (0.50) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL26012277 | 0.91 | MAOA (0.50) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL14790647 | 0.88 | ADRB1 (0.46) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL2627278 | 0.88 | NR3C1 (0.43) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL13245957 | 0.87 | NAMPT (0.48) | MAPTMEN1KMT2ANR3C1PGR | |
| Hydrochloric Acid SCHEMBL14782734 | 0.86 | ADRB1 (0.45) | MAPTMEN1KMT2ANR3C1PGR | |
| SCHEMBL2984932 | 0.82 | MAPT (0.59) | MAPTMEN1KMT2AFUCA1ALDH1A1 | |
| SCHEMBL13245958 | 0.82 | MAPT (0.59) | MAPTMEN1KMT2AFUCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115433127-A | Quinolinamines compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| EP-2342185-B1 | SULFON SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2342185-B1 | SULFON SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802686-B2 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1673352-B1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CD AND/OR VEGF-INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | BAYER SCHERING PHARMA AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| WO-2007146719-A2 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1673352-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005037800-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, CDK1, FLT1 | MAPT 3750/4885MEN1 3930/4885KMT2A 1485/4885 |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | MAPT 96/4885MEN1 1630/4885KMT2A 1834/4885 |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | CDK2, CDK1, FLT1 | MAPT 3750/4885MEN1 3930/4885KMT2A 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.